Finland · Delayed Price · Currency is EUR Remedy Entertainment Oyj Statistics
Total Valuation
HEL:REMEDY has a market cap or net worth of EUR 255.77 million. The enterprise value is 244.01 million.
| Market Cap | 255.77M |
| Enterprise Value | 244.01M |
Important Dates
The last earnings date was Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HEL:REMEDY has 13.59 million shares outstanding. The number of shares has increased by 0.18% in one year.
| Current Share Class | 13.59M |
| Shares Outstanding | 13.59M |
| Shares Change (YoY) | +0.18% |
| Shares Change (QoQ) | -0.54% |
| Owned by Insiders (%) | 27.65% |
| Owned by Institutions (%) | 19.21% |
| Float | 9.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 44.02 |
| PS Ratio | 4.87 |
| PB Ratio | 4.66 |
| P/TBV Ratio | 5.39 |
| P/FCF Ratio | 17.67 |
| P/OCF Ratio | 16.38 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 16.86 |
Financial Position
The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.98 |
| Quick Ratio | 2.98 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.23 |
| Interest Coverage | -2.96 |
Financial Efficiency
Return on equity (ROE) is -25.42% and return on invested capital (ROIC) is -8.71%.
| Return on Equity (ROE) | -25.42% |
| Return on Assets (ROA) | -2.53% |
| Return on Invested Capital (ROIC) | -8.71% |
| Return on Capital Employed (ROCE) | -5.11% |
| Weighted Average Cost of Capital (WACC) | 9.81% |
| Revenue Per Employee | 138,509 |
| Profits Per Employee | -41,744 |
| Employee Count | 379 |
| Asset Turnover | 0.58 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -3.58M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +31.79% in the last 52 weeks. The beta is 1.06, so HEL:REMEDY's price volatility has been similar to the market average.
| Beta (5Y) | 1.06 |
| 52-Week Price Change | +31.79% |
| 50-Day Moving Average | 15.66 |
| 200-Day Moving Average | 14.39 |
| Relative Strength Index (RSI) | 75.26 |
| Average Volume (20 Days) | 10,787 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HEL:REMEDY had revenue of EUR 52.50 million and -15.82 million in losses. Loss per share was -1.16.
| Revenue | 52.50M |
| Gross Profit | 43.81M |
| Operating Income | -3.70M |
| Pretax Income | -19.40M |
| Net Income | -15.82M |
| EBITDA | -1.64M |
| EBIT | -3.70M |
| Loss Per Share | -1.16 |
Balance Sheet
The company has 29.60 million in cash and 17.84 million in debt, with a net cash position of 11.76 million or 0.87 per share.
| Cash & Cash Equivalents | 29.60M |
| Total Debt | 17.84M |
| Net Cash | 11.76M |
| Net Cash Per Share | 0.87 |
| Equity (Book Value) | 54.91M |
| Book Value Per Share | 4.04 |
| Working Capital | 25.40M |
Cash Flow
In the last 12 months, operating cash flow was 15.61 million and capital expenditures -1.14 million, giving a free cash flow of 14.47 million.
| Operating Cash Flow | 15.61M |
| Capital Expenditures | -1.14M |
| Depreciation & Amortization | 2.06M |
| Net Borrowing | -1.44M |
| Free Cash Flow | 14.47M |
| FCF Per Share | 1.07 |
Margins
Gross margin is 83.46%, with operating and profit margins of -7.04% and -30.14%.
| Gross Margin | 83.46% |
| Operating Margin | -7.04% |
| Pretax Margin | -36.96% |
| Profit Margin | -30.14% |
| EBITDA Margin | -3.12% |
| EBIT Margin | -7.04% |
| FCF Margin | 27.57% |
Dividends & Yields
HEL:REMEDY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.18% |
| Shareholder Yield | -0.18% |
| Earnings Yield | -6.19% |
| FCF Yield | 5.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for HEL:REMEDY is 20.50, which is 8.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 20.50 |
| Price Target Difference | 8.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 24.21% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HEL:REMEDY has an Altman Z-Score of 4.61 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.61 |
| Piotroski F-Score | 3 |